Prokopenko E, Scherbakova E, Vatazin A, Pasov S, Budnikova N, Agafonova S
Moscow Regional Research Clinical Institute, Department of Dialysis and Kidney Transplantation, Moscow, Russian Federation.
Drugs Exp Clin Res. 2005;31(5-6):199-205.
The aim of this study was to investigate infectious complications in renal transplant recipients (RTRs) receiving mycophenolate mofetil (MMF) for prevention of acute transplant rejection. A group of RTRs (n = 47) receiving 1.0-2.0 g/day of MMF with cyclosporine A (CsA) and prednisolone to maintain immunosuppression was compared with a group (n = 47) taking triple immunosuppressive therapy including azathioprine. In both groups the etiology and incidence of infections were evaluated. During 2 years post-transplant, various infections developed in 72.3% of patients who received MMF and in 93.6% of those who received azathioprine. The incidence of viral infections was 53.2% in the MMF group and 59.6% in the azathioprine group and the incidence of bacterial infection was 55.3% and 70.2%, respectively There were two cases of active tuberculosis in the azathioprine group and one in the MMF group. MMF 1.0-2.0 g/day does not increase infection rates in RTRs compared with azathioprine.
本研究旨在调查接受霉酚酸酯（MMF）预防急性移植排斥反应的肾移植受者（RTR）的感染并发症。将一组接受1.0 - 2.0 g/天MMF联合环孢素A（CsA）和泼尼松龙以维持免疫抑制的RTR（n = 47）与一组接受包括硫唑嘌呤在内的三联免疫抑制治疗的RTR（n = 47）进行比较。评估两组感染的病因和发生率。移植后2年内，接受MMF的患者中有72.3%发生了各种感染，接受硫唑嘌呤的患者中有93.6%发生了各种感染。MMF组病毒感染发生率为53.2%，硫唑嘌呤组为59.6%，细菌感染发生率分别为55.3%和70.2%。硫唑嘌呤组有2例活动性结核病，MMF组有1例。与硫唑嘌呤相比，1.0 - 2.0 g/天的MMF不会增加RTR的感染率。
